IBRX

ImmunityBio Inc

Feb 26 • 01:09PM ET

9.26

-0.28 -2.94 %

Healthcare • Biotechnology • USA • NASD

Today, 7:36 AMImmunityBio reports statistically significant interim benefit in duration of complete response vs BCG alone in QUILT 2.005 ANKTIVA+BCG NMIBC, plans BLA filing by Q4 2026

Peers: MRNA BNTX NVAX PFE VRTX REGN GILD ALNY AMGN BIIB

| Held by: XBI VTI IWM VB IBB VBK VXF IWO SCHA VTWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.39	Insider Own	66.47%	Shs Outstand	1.01B	Perf Week	7.55%
Market Cap	9.52B	Forward P/E	-	EPS next Y	-0.05	Insider Trans	-0.06%	Shs Float	344.74M	Perf Month	55.63%
Enterprise Value	10.12B	PEG	-	EPS next Q	-0.08	Inst Own	16.59%	Short Float	39.21%	Perf Quarter	330.70%
Income	-351.40M	P/S	84.03	EPS this Y	23.13%	Inst Trans	7.58%	Short Ratio	4.03	Perf Half Y	289.08%
Sales	113.29M	P/B	-	EPS next Y	83.99%	ROA	-79.43%	Short Interest	135.16M	Perf YTD	367.68%
Book/sh	-0.49	P/C	39.21	EPS next 5Y	-	ROE	-	52W High	12.43 -25.50%	Perf Year	208.67%
Cash/sh	0.24	P/FCF	-	EPS past 3/5Y	28.42% 15.60%	ROIC	-104.92%	52W Low	1.83 406.01%	Perf 3Y	257.53%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	678.62% 299.74%	Gross Margin	85.63%	Volatility	20.00% 14.98%	Perf 5Y	-71.52%
Dividend TTM	-	EV/Sales	89.36	EPS Y/Y TTM	34.94%	Oper. Margin	-226.00%	ATR (14)	1.19	Perf 10Y	24.97%
Dividend Ex-Date	-	Quick Ratio	5.08	Sales Y/Y TTM	668.31%	Profit Margin	-310.18%	RSI (14)	63.01	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.10	EPS Q/Q	32.90%	SMA20	26.13%	Beta	-0.11	Target Price	12.60
Payout	-	Debt/Eq	-	Sales Q/Q	406.95%	SMA50	86.28%	Rel Volume	1.45	Prev Close	9.54
Employees	691	LT Debt/Eq	-	Earnings	Feb 23 BMO	SMA200	194.67%	Avg Volume	33.57M	Price	9.26
IPO	Jul 28, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	21.57% -0.20%	Trades		Volume	28,427,942	Change	-2.94%

Date	Action	Analyst	Rating Change	Price Target Change
May-20-25	Upgrade	Piper Sandler	Neutral → Overweight	$5
Mar-06-25	Initiated	H.C. Wainwright	Buy	$8
Jan-10-25	Initiated	BTIG Research	Buy	$6
May-12-23	Downgrade	Piper Sandler	Overweight → Neutral	$10 → $4
Aug-03-22	Initiated	Jefferies	Buy	$8

Today 08:57AM	ImmunityBio Investors Rally Behind Cancer Trial Milestone (Benzinga)
07:30AM	ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA Plus BCG Versus BCG Alone in BCG-Nave Non-Muscle Invasive Bladder Cancer Carcinoma In Situ (Business Wire)
02:08AM	ImmunityBio (IBRX) Loses 17% to Profit-Taking After Intra-Day High (Insider Monkey)
Feb-25-26 01:02PM	ImmunityBio Supersedes Expectations With Fivefold Revenue Increase (Benzinga) -17.40%
09:09AM	ImmunityBio's 471% Stock Rally Could Enter Next Round If Shorts Capitulate (Benzinga)
09:00AM	Loading…
09:00AM	Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026 (PR Newswire)
06:19AM	ImmunityBio (IBRX) Reports 700% Revenue Surge Driven by Rapid ANKTIVA Adoption (Insider Monkey)
01:44AM	ImmunityBio (IBRX) Skyrockets as Anktiva Propels 671% Revenue Jump (Insider Monkey)
Feb-23-26 04:15PM	ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute and Richard Nixon Foundation "Cancer 2035: A Roadmap for the Future" Summit (Business Wire) +12.99% +17.50%
12:34PM	ImmunityBio Explodes To Near 52-Week High As Bladder Cancer Drug Anktiva Drives Massive 700% Revenue Growth (Benzinga)
10:35AM	ImmunityBio (IBRX) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
09:40AM	ImmunityBio: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally (Business Wire)
Feb-20-26 09:05AM	ImmunityBio Taps 85-Person Sales Team to Launch Its Bladder Cancer Drug In European Countries (Benzinga)
08:30AM	ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA in Saudi Arabia for Bladder and Lung Cancer Patients (Business Wire)
11:37AM	Loading…
Feb-19-26 11:37AM	ImmunityBio Holds Golden Cross As Stock Trades 170% Above 200-Day Average (Benzinga)
09:00AM	ImmunityBio Expands Access to ANKTIVA in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch (Business Wire)
07:34AM	ImmunityBio Wins EU Nod for Bladder Cancer Combo Therapy, Stock Up (Zacks)
06:08AM	ImmunityBio (IBRX) Soars to New High on Anktiva Future Expansion (Insider Monkey)
06:03AM	ImmunityBio (IBRX) Moves 41.9% Higher: Will This Strength Last? (Zacks)
Feb-18-26 07:38PM	ImmunityBio (IBRX) Clinical Trial for Lymphona Drug Follows $505M Convertible Note Change (Insider Monkey) +41.86%
12:02PM	What's Behind The Jump In ImmunityBio Stock? (Benzinga)
09:00AM	ImmunityBio Receives Authorization from the European Commission for ANKTIVA with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries (Business Wire)
Feb-17-26 11:17AM	New Treatment Modalities Are Reaching Cancers That Resisted Everything Else (PR Newswire)
09:44AM	Why Is ImmunityBio Stock Gaining Tuesday? (Benzinga)
06:07AM	ImmunityBio Reports Productive Regulatory Engagement with Saudi Food and Drug Authority at USA-Saudi Biotech Alliance Meeting Hosted by the Ministry of Investment of Saudi Arabia (Business Wire)
Feb-13-26 03:32PM	Top 10 Most Shorted Stocks: CleanSpark, Hims & Hers And More (Benzinga) -10.20%
Feb-10-26 07:42AM	ImmunityBio (IBRX) Jumps Ahead of Oncology Event (Insider Monkey) -5.34%
Feb-05-26 07:58AM	Rapid Innovation is Reshaping Oncology: Stocks in Focus (Zacks)
Feb-02-26 02:08PM	These 10 Stocks Could Be Short Squeeze Targets: Lucid, Kohl's, Avis and More (Benzinga)
09:55AM	Loading…
09:55AM	Piper Sandler See Label Expansion Potential for ImmunityBio, Inc. (IBRX)'s ANKTIVA Following QUILT Data (Insider Monkey)
07:00AM	ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA (ResQ215B) in Indolent Lymphomas (Business Wire)
Jan-30-26 02:51PM	These 10 Stocks Just Had Their Best Or Worst Month Ever - And You Might Not Know Why (Benzinga) +5.75%
Jan-28-26 10:30AM	ImmunityBio (IBRX) Sheds 4% on Profit-Taking After 14-Day Run (Insider Monkey)
09:15AM	Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment (PR Newswire)
Jan-23-26 07:00AM	ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA Plus CAR-NK, Chemo-Free Therapy (Business Wire) -12.13%
Jan-22-26 09:10AM	Jim Cramer on ImmunityBio: "I Really Think That You Have to Take Profits in Some of That" (Insider Monkey) +6.07%
Jan-21-26 10:46AM	ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission (Zacks) +6.79%
02:28AM	ImmunityBio (IBRX) Rockets on 12th Day, Hits Fresh High (Insider Monkey)
Jan-20-26 08:44PM	Lightning Round: Shell is 'just an ok oil company', says Jim Cramer (CNBC TV) +17.39%
01:47PM	FDA Talks Set Path For Expanded Use For ImmunityBio's Anktiva In Bladder Cancer (Benzinga)
01:19PM	ImmunityBio Extends Rally After FDA Talks (GuruFocus.com)
04:00AM	ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA in BCG-Unresponsive Papillary Bladder Cancer (Business Wire)
Jan-19-26 09:15PM	ImmunityBio (IBRX) Soars 137% on Expansion Plan, Clinical Results (Insider Monkey)
05:21PM	ImmunityBio, Inc. (IBRX): A Bull Case Theory (Insider Monkey)
10:36AM	ImmunityBio Shares Surge on Updated Durable Lymphoma Study Results (Zacks)
Jan-17-26 03:09AM	ImmunityBio (IBRX) Rallies on 11th Day, Hits 52-Week High on Strong Clinical Trial Results (Insider Monkey)
Jan-16-26 02:05PM	Why ImmunityBio Stock Is Skyrocketing Again Today (Motley Fool) +39.75%
12:52PM	ImmunityBio Stock Soars On Cancer Trial Progress, FDA Timeline (Benzinga)
12:50PM	These Stocks Are Todays Movers: GE Vernova, Constellation Energy, Micron, AST SpaceMobile, Novo Nordisk, and More (Barrons.com)
11:33AM	ImmunityBio (IBRX) Extends Gains to 10th Day on 700% Anktiva Sales Jump; Time to Book Profits? (Insider Monkey)
11:04AM	ImmunityBio's 700% Revenue Boom Becomes Citadel's Latest I-Told-You-So (Benzinga)
10:41AM	Looking For A Short Squeeze? 10 Stocks Ready To Rocket (Benzinga)
09:40AM	This Biotech Stock Is Up More Than 100% This Year. Why Its Soaring Again Today. (Barrons.com)
09:27AM	Ford & BYD reportedly in talks to partner, PNC rises on earnings (Yahoo Finance Video)
08:27AM	Micro shares surge on share buying by board member, and more stocks on the move (MarketWatch)
08:00AM	IRS Proposes Tax Changes That Could Target Sovereign Wealth Funds' US Investments: Report (Benzinga)
08:00AM	Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape (PR Newswire)
07:00AM	ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma (Business Wire)
07:00AM	ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA Plus BCG (Business Wire)
05:53AM	These Stocks Are Today's Movers: Micron, Sandisk, J.B. Hunt, HP Inc., ImmunityBio, and More (Barrons.com)
05:52AM	This Biotech Stock Is Up 100% This Year. Why It's Soaring Again Today. (Barrons.com)
05:46AM	Stock Market Today: Dow Jones, S&P 500 Futures Gain Following Stellar Chipmaker Rally-Chevron, Paysafe, J.B. Hunt Transport In Focus (Benzinga)
Jan-15-26 08:26PM	Robinhood, TSMC, Reddit, ImmunityBio And AST Spacemobile: Why These 5 Stocks Are On Investors' Radars Today (Benzinga) +30.79%
12:43PM	ImmunityBio Clocks 700% Revenue Surge In 2025 From Lead Bladder Cancer Drug (Benzinga)
08:30AM	ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue-a 700% increase year-over-year (Business Wire)
Jan-14-26 02:13PM	H.C Wainwright Asserts Buy Stance as ImmunityBio, Inc. (IBRX) Achieves Positive Results on Bladder Cancer Treatment (Insider Monkey) +7.09%
09:15AM	ImmunityBio announces results from Anktiva clinical program (TipRanks)
08:30AM	Saudi FDA Grants Accelerated Approval to ImmunityBios ANKTIVA In Combination with Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer (Business Wire)
08:30AM	Saudi FDA Grants Accelerated Approval to ImmunityBios ANKTIVA for Non-Muscle Invasive Bladder Cancer with Carcinoma In-Situ (Business Wire)
07:10AM	ImmunityBio (IBRX) Extends Rally on 8th Day on Strong Clinical Trial Results (Insider Monkey)
Jan-13-26 08:30AM	ImmunityBio Announces Positive Results Demonstrating ANKTIVA as a Lymphocyte Stimulating Agent in Combination With Checkpoint Inhibitors in Non-Small Cell Lung Cancer (Business Wire) +8.88%
Jan-12-26 08:30AM	NantWorks and ImmunityBio Announce Inaugural U.S.-Saudi Biotech Alliance Summit to Advance Immunotherapy 2.0 and Global Health Security (Business Wire) +11.16%
Dec-29-25 10:15AM	3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround (Zacks)
09:00AM	ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of 100 Most Influential People in Oncology in 2025 (Business Wire)
Dec-18-25 10:40AM	3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment (Zacks)
05:23AM	Is ImmunityBio, Inc. (IBRX) The Best NASDAQ Stock Under $10 to Buy? (Insider Monkey)
01:14AM	Jefferies Lifts ImmunityBio Inc. (IBRX) Price Target Following Anktiva European Expansion (Insider Monkey)
Dec-16-25 09:00AM	ANKTIVA with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer (Business Wire)
Dec-13-25 07:15AM	ImmunityBio (IBRX) Climbs 7.76% on Europe Expansion (Insider Monkey)
Dec-12-25 06:10AM	ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ-A First in Europe (Business Wire) +7.76%
Dec-05-25 03:06PM	ImmunityBio, Inc. (IBRX): A Bull Case Theory (Insider Monkey)
Dec-03-25 11:08AM	ImmunityBio (IBRX) Slashes 9% on Lack of Leads (Insider Monkey) +5.26%
Dec-01-25 09:10AM	ImmunityBio (IBRX) Soars 10.8% Ahead of Health Conferences (Insider Monkey)
Nov-30-25 05:38AM	Is ImmunityBio Inc. (IBRX) The Best US Stock To Buy Under $20? (Insider Monkey)
Nov-24-25 09:47AM	H.C. Wainwright Asserts Buy Rating on Immunitybio Inc. (IBRX) as Net Loss Narrows on Robust Product Revenue (Insider Monkey)
Nov-13-25 09:00AM	New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations (Business Wire)
Nov-05-25 05:05AM	ImmunityBio: Q3 Earnings Snapshot (Associated Press Finance)
Nov-04-25 10:12PM	Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024 (Business Wire) -7.96%
Nov-03-25 05:40PM	Myriad Genetics (MYGN) Reports Break-Even Earnings for Q3 (Zacks) -5.83%
Oct-01-25 01:45PM	ImmunityBio, Inc. (IBRX) Reports Strong Q2 Growth, Eyes Lung Cancer and NMIBC Expansion (Insider Monkey)
Sep-30-25 02:49PM	Wall Street Bullish on ImmunityBio (IBRX) Since the Announcement of New Findings From QUILT-3.055 Study (Insider Monkey)
Sep-20-25 02:43AM	ImmunityBio's (IBRX) ANKTIVA Shows Survival Gains in Lung Cancer Patients (Insider Monkey)
Sep-17-25 06:22PM	Biotech Breakouts: 3 Stocks With Massive Upside Potential (MarketBeat)
Sep-16-25 12:29PM	Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals (PR Newswire)
Sep-15-25 08:17AM	H.C. Wainwright Reiterates Buy Rating on ImmunityBio, Keeps PT at $8 (Insider Monkey) +5.38%
Sep-08-25 08:30AM	ImmunityBio's ANKTIVA Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy (Business Wire)
Aug-31-25 12:17AM	ImmunityBio (IBRX) Reports Initial Study Data Showing 100% Disease Control in Patients With Recurrent Glioblastoma (Insider Monkey)
Aug-28-25 10:44AM	FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone (PR Newswire)
05:04AM	ImmunityBio, Inc. (IBRX) Targets Lymphopenia with Cancer BioShield Platform (Insider Monkey)

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Selecky Christobel	Director	Feb 23 '26	Option Exercise	2.98	25,000	74,500	25,000	Feb 24 08:05 PM
Selecky Christobel	Director	Feb 23 '26	Sale	10.00	25,000	250,000	0	Feb 24 08:05 PM
Sachs David C.	Chief Financial Officer	Feb 22 '26	Option Exercise	0.00	40,650	0	320,825	Feb 24 08:05 PM
SOON-SHIONG PATRICK	See remarks	Feb 22 '26	Option Exercise	0.00	114,329	0	29,816,081	Feb 24 08:05 PM
LAUER REGAN J	Chief Accounting Officer	Feb 22 '26	Option Exercise	0.00	4,065	0	117,548	Feb 24 08:05 PM
Adcock Richard	CEO & President	Feb 22 '26	Option Exercise	0.00	152,439	0	637,904	Feb 24 08:04 PM
Simon Barry J.	Director	Feb 22 '26	Option Exercise	0.00	15,243	0	3,096,847	Feb 24 08:03 PM
Simon Barry J.	Director	Feb 23 '26	Sale	10.25	165,000	1,691,102	2,925,821	Feb 24 08:03 PM
Simon Barry J.	Director	Feb 20 '26	Sale	9.25	10,000	92,500	3,081,604	Feb 24 08:03 PM
CHRISTOBEL SELECKY	Director	Feb 23 '26	Proposed Sale	8.70	25,000	217,500		Feb 23 04:28 PM
SOON-SHIONG PATRICK	See remarks	Feb 10 '26	Option Exercise	0.00	274,122	0	29,820,312	Feb 12 09:29 PM
Sachs David C.	Chief Financial Officer	Feb 10 '26	Option Exercise	0.00	82,236	0	322,818	Feb 12 08:50 PM
LAUER REGAN J	Chief Accounting Officer	Feb 10 '26	Option Exercise	0.00	5,482	0	115,740	Feb 12 08:50 PM
Adcock Richard	CEO & President	Feb 10 '26	Option Exercise	0.00	274,122	0	625,513	Feb 12 08:50 PM
Simon Barry J.	Director	Jan 20 '26	Sale	7.20	151,967	1,094,297	3,091,604	Jan 21 08:34 PM
Selecky Christobel	Director	Jan 16 '26	Option Exercise	2.98	50,000	149,000	50,000	Jan 21 08:33 PM
Selecky Christobel	Director	Jan 20 '26	Option Exercise	2.98	25,000	74,500	25,000	Jan 21 08:33 PM
Selecky Christobel	Director	Jan 16 '26	Sale	5.00	50,000	250,000	0	Jan 21 08:33 PM
Selecky Christobel	Director	Jan 20 '26	Sale	7.51	25,000	187,650	0	Jan 21 08:33 PM
CHRISTOBEL SELECKY	Director	Jan 20 '26	Proposed Sale	5.52	25,000	138,000		Jan 20 04:29 PM
Simon Barry J.	Officer	Jan 20 '26	Proposed Sale	10.33	571,967	5,909,546		Jan 20 11:05 AM
CHRISTOBEL SELECKY	Director	Jan 16 '26	Proposed Sale	3.95	50,000	197,500		Jan 16 04:22 PM
Sachs David C.	Chief Financial Officer	Dec 31 '25	Option Exercise	0.00	30,397	0	256,017	Jan 05 06:11 PM
Adcock Richard	CEO & President	Dec 31 '25	Option Exercise	0.00	34,483	0	368,901	Jan 05 06:10 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IBRX

ImmunityBio Inc

Upgrade your FINVIZ experience